Jie-Ying Xi

Jie-Ying Xi

Auto-generated profile, based on publicly available information

Jie-Ying Xi

Department of hematology, First affiliated hospital of Xi'an Jiaotong University, Yanta West Road, Xi'an, 710061, Shaanxi, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Trials
Verified
Journal Article
Open access
PDF file
XZXinxin Zhang
Xinxin Zhang
HZHuiyun Zhang
Huiyun Zhang
LCLimei Chen
Limei Chen
MWMengchang Wang
Mengchang Wang
JXJieying Xi
Jieying Xi
HWHuaiyu Wang
Huaiyu Wang
The treatment of acute promyelocytic leukemia (APL) has been revolutionized in the past two decades by the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). It suggests that non-high-risk APL patients can be cured without chemotherapy. However, ATRA plus chemotherapy is still the standard therapy for the high-risk patients. Central nervous system (CNS) relapse remains a significant cause of treatment failure in high-risk patients. However, increasing the ATO concentration in cerebrospinal fluid (CSF) may reduce CNS relapse in high-risk patients. Mannitol can allow ATO to penetrate the blood-brain barrier (BBB) and reach therapeutically effective levels in the CSF. It is used for the treatment of CNS relapse in patients APL. We compare ATRA-ATO with ATRA-ATO plus chemotherapy in both high-risk and non-high-risk patients with APL. This study was designed as a multicenter randomized controlled trial. Patients with APL were randomly assigned into two groups: the ATRA-ATO group (experimental group) and the ATRA-ATO plus chemotherapy group (control group). The experimental group receives therapy with ATRA-ATO for induction, consolidation and maintenance therapy. In the high-risk patients, mannitol will be used with ATO in the consolidation and maintenance therapy. Hydroxyurea will be used in patients who developed leukocytosis in the induction therapy. The control group receives therapy with ATRA-ATO plus chemotherapy for induction and consolidation therapy. In this study, a randomized clinical trial design is described. It aims to compare the efficacy of ATRA-ATO versus ATRA-ATO plus chemotherapy in all-risk patients with APL. Chinese Clinical Trials Registry, ID: ChiCTR-IPR- 15006821 . Registered on 27 July 2015.

2 January 2020 in Trials
Verified
Journal Article
Open access
PDF file
XZXinxin Zhang
Xinxin Zhang
LLLi Liu
Li Liu
YYYazhou Yao
Yazhou Yao
SGSha Gong
Sha Gong
MWMengchang Wang
Mengchang Wang
HWHuaiyu Wang
Huaiyu Wang
Background: Acute promyelocytic leukemia (APL) is a highly curable disease when treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO). The combination of ATO and ATRA has become the standard therapeutic protocol for induction therapy in non-high-risk APL. An oral arsenic realgar-indigo naturalis formula (RIF) has also showed high efficacy and it has a more convenient route of administration than the standard intravenous regimen. Unlike in previous trials, the arsenical agent was used simultaneously with ATRA during post-remission therapy in this trial. Methods: This study was designed as a multicenter, randomized controlled trial. The trial has a non-inferiority design with superiority being explored if non-inferiority is identified. All patients receive ATRA-ATO during the induction therapy. After achieving hematologic complete remission (HCR), patients were randomly assigned (1:1) to receive treatment with ATRA-RIF (experimental group) or ATRA-ATO (control group) as the consolidation therapy. During the consolidation therapy, the two groups receive ATRA plus RIF or intravenous ATO 2 weeks on and 2 to ~ 4 weeks off until molecular complete remission (MCR), then ATRA and oral RIF 2 weeks on and 2 to ~ 4 weeks off giving a total of six courses. Discussion: This trial aims to compare the efficacy of ATRA-ATO versus ATRA-RIF in non-high-risk patients with APL, to demonstrate that oral RIF application reduces the total hospitalization days and medical costs. The simple schedule was studied in this trial. Trial registration: ClinicalTrials.gov, NCT02899169. Registered on 14 September 2016.

21 June 2012 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
PHPengcheng He
Pengcheng He
YLYanfeng Liu
Yanfeng Liu
MZMei Zhang
Mei Zhang
XWXiaoning Wang
Xiaoning Wang
HWHuaiyu Wang
Huaiyu Wang
JZJing Zhao
Jing Zhao
To explore optimum conditions for establishing a two‑dimensional gel electrophoresis (2-DE) map of the human acute promyelocytic leukemia (APL) cell line NB4 and to analyze its protein profiles, we extracted total proteins from NB4 cells using cell disruption, liquid nitrogen freeze-thawing and fracturing by ultrasound, and quantified the extracted protein samples using Bradford's method. 2-DE was applied to separate the proteins, which were silver-stained in the gel. Well‑separated protein spots were selected from the gel using the ImageMaster™ 2D Platinum analysis system. Moreover, the effects of various protein sample sizes (140, 160 and 180 µg) on the 2-DE maps of the NB4 cells were determined and compared. Matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS), peptide mass fingerprinting (PMF) and database searching were used to identify the proteins. When the quantity of loading proteins was 160 µg, clear, well-resolved, reproducible 2-DE proteomic profiles of the NB4 cells were obtained. The average number of protein spots in 3 gels was 1160±51 with an average matching rate of 81%. A total of 10 proteins were identified by mass spectrometry and database queries, certain proteins were products of oncogenes and others were involved in cell cycle regulation and signal transduction. In summary, 2-DE profiles of the proteome of NB4 cells were established and certain proteins were identified by MALDI-TOF-MS and PMF which lay the foundation of further proteomic research of NB4 cells. These data should be useful for establishing a human APL proteome database.

1 October 2014
Verified
Journal Article
Closed access
HLHua-Sheng Liu
Hua-Sheng Liu
MZMing-Shang Zhu
Ming-Shang Zhu
HZHai-Ling Zhang
Hai-Ling Zhang
SWShuang-Yu Wei
Shuang-Yu Wei
XWXiao-Ning Wang
Xiao-Ning Wang
MZMei Zhang
Mei Zhang

1 October 2013
Verified
Journal Article
Closed access
HLHuasheng Liu
Huasheng Liu
XWXiao-Ning Wang
Xiao-Ning Wang
HLHai-Bo Liu
Hai-Bo Liu
XLXin Liu
Xin Liu
PHPeng-Cheng He
Peng-Cheng He
MZMei Zhang
Mei Zhang

1 December 2013
Verified
Journal Article
Closed access
XWXiao-Ning Wang
Xiao-Ning Wang
MZMei Zhang
Mei Zhang
PHPeng-Cheng He
Peng-Cheng He
XLXin Liu
Xin Liu
JXJie-Ying Xi
Jie-Ying Xi
CSChun-Hong Sun
Chun-Hong Sun